

Accumulation of Amyloid Precursor Protein in the Mitochondria of  
Human Alzheimer's Disease Brain Is Associated with Mitochondrial Dysfunction

Journal of Neuroscience

26, 9057-9068

DOI: 10.1523/jneurosci.1469-06.2006

Citation Report

#	ARTICLE	IF	CITATIONS
1	Alzheimer's APP mangles mitochondria. <i>Nature Medicine</i> , 2006, 12, 1241-1243.	15.2	123
2	Feeling pain? Who's your daddy.... <i>Nature Medicine</i> , 2006, 12, 1243-1244.	15.2	7
3	Quantitative Cytochrome Oxidase Histochemistry: Applications in Human Alzheimer's Disease and Animal Models. <i>Journal of Histochemistry</i> , 2007, 30, 235-247.	0.2	11
4	Pathogenic role of mitochondrial amyloid- $\beta$ peptide. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1517-1525.	1.4	28
5	The Function of TIM22 in the Insertion of Inner Membrane Proteins in Mitochondria. <i>The Enzymes</i> , 2007, , 367-385.	0.7	0
6	Mitochondrial Translocation of Amyloid Precursor Protein and its Cleaved Products: Relevance to Mitochondrial Dysfunction in Alzheimer's Disease. <i>Reviews in the Neurosciences</i> , 2007, 18, 343-54.	1.4	19
7	Molecular determinants of Alzheimer's disease A $\beta$ peptide neurotoxicity. <i>Future Neurology</i> , 2007, 2, 397-409.	0.9	9
8	Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts. <i>Progress in Neurobiology</i> , 2007, 82, 11-32.	2.8	155
9	Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. <i>Mitochondrion</i> , 2007, 7, 297-310.	1.6	239
10	Mitochondrial Cascade Hypothesis of Alzheimer's Disease: Myth or Reality?. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 1631-1646.	2.5	48
11	Mitochondrial Dysfunction in Aging and Alzheimer's Disease: Strategies to Protect Neurons. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 1647-1658.	2.5	169
12	Chronic exposure to sub-lethal beta-amyloid (A $\beta$ ) inhibits the import of nuclear-encoded proteins to mitochondria in differentiated PC12 cells*. <i>Journal of Neurochemistry</i> , 2007, 103, 1989-2003.	2.1	65
13	Regulation of mitochondrial oxidative phosphorylation through cell signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1701-1720.	1.9	230
14	Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. <i>Free Radical Biology and Medicine</i> , 2007, 43, 809-817.	1.3	125
15	Insights into amyloid- $\beta$ -induced mitochondrial dysfunction in Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2007, 43, 1569-1573.	1.3	93
16	Amyloid Precursor Protein and Mitochondrial Dysfunction in Alzheimer's Disease. <i>Neuroscientist</i> , 2007, 13, 626-638.	2.6	82
17	Causes of oxidative stress in Alzheimer disease. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2202-2210.	2.4	312
18	Mitochondrial degeneration in dystrophic neurites of senile plaques may lead to extracellular deposition of fine filaments. <i>Brain Structure and Function</i> , 2007, 212, 195-207.	1.2	53

#	ARTICLE	IF	CITATIONS
19	Mechanisms of amyloid plaque pathogenesis. <i>Acta Neuropathologica</i> , 2007, 114, 551-571.	3.9	85
20	Molecular Genetics of a Patient with Mohrâ€™Tranebjaerg Syndrome due to a New Mutation in the DDP1 Gene. <i>NeuroMolecular Medicine</i> , 2007, 9, 285-291.	1.8	26
21	Delineating the Mechanism of Alzheimerâ€™s Disease AÎ² Peptide Neurotoxicity. <i>Neurochemical Research</i> , 2008, 33, 526-532.	1.6	105
22	Mitochondrial Medicine for Aging and Neurodegenerative Diseases. <i>NeuroMolecular Medicine</i> , 2008, 10, 291-315.	1.8	197
23	From proliferative to neurological role of an hsp70 stress chaperone, mortalin. <i>Biogerontology</i> , 2008, 9, 391-403.	2.0	43
25	Mitochondrial Disorders in the Nervous System. <i>Annual Review of Neuroscience</i> , 2008, 31, 91-123.	5.0	488
26	Age related mitochondrial degenerative disorders in humans. <i>Biotechnology Journal</i> , 2008, 3, 750-756.	1.8	59
27	Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. <i>Nature Medicine</i> , 2008, 14, 1097-1105.	15.2	833
28	Intra-mitochondrial degradation of Tim23 curtails the survival of cells rescued from apoptosis by caspase inhibitors. <i>Cell Death and Differentiation</i> , 2008, 15, 545-554.	5.0	21
29	Mitochondrial fusion, fission and autophagy as a quality control axis: The bioenergetic view. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2008, 1777, 1092-1097.	0.5	556
30	Non-tau based neuronal degeneration in Alzheimer's disease â€™ an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. <i>Brain Research</i> , 2008, 1213, 152-165.	1.1	39
31	Mitochondrial Import and Accumulation of Î±-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain. <i>Journal of Biological Chemistry</i> , 2008, 283, 9089-9100.	1.6	870
32	Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. <i>Trends in Molecular Medicine</i> , 2008, 14, 45-53.	3.5	799
33	The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?. <i>Trends in Neurosciences</i> , 2008, 31, 251-256.	4.2	220
34	Mechanisms of AÎ² mediated neurodegeneration in Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 181-198.	1.2	220
35	Dynamin-Like Protein 1 Reduction Underlies Mitochondrial Morphology and Distribution Abnormalities in Fibroblasts from Sporadic Alzheimer's Disease Patients. <i>American Journal of Pathology</i> , 2008, 173, 470-482.	1.9	308
36	Multi-target-Directed Ligands To Combat Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 347-372.	2.9	961
37	Amyloid-Î² overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19318-19323.	3.3	734

#	ARTICLE	IF	CITATIONS
38	Isoflavones Promote Mitochondrial Biogenesis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 536-543.	1.3	180
39	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 45-53.	4.9	443
40	ANOTHER "NEW DRUG IN THE AD PIPELINE"?™. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2008, 8, 5-6.	0.0	0
41	Oxidative Stress Signaling in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2008, 5, 525-532.	0.7	250
42	Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?. <i>Current Alzheimer Research</i> , 2008, 5, 457-468.	0.7	54
43	The concept of translocational regulation. <i>Journal of Cell Biology</i> , 2008, 182, 225-232.	2.3	112
44	The amyloid $\beta$ -peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13145-13150.	3.3	598
45	Oxidative Stress in Vascular Dementia and Alzheimer's Disease: A Common Pathology. <i>Journal of Alzheimer's Disease</i> , 2008, 17, 245-257.	1.2	195
46	An update on the toxicity of A $\beta$ in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1033.	1.0	32
47	Multiple SNPs Within and Surrounding the Apolipoprotein E Gene Influence Cerebrospinal Fluid Apolipoprotein E Protein Levels. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 255-266.	1.2	75
48	Mitochondria, Cognitive Impairment, and Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2009, 2009, 1-8.	1.1	44
49	A New Function of Human HtrA2 as an Amyloid- $\beta$ Oligomerization Inhibitor. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 281-294.	1.2	40
50	Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. <i>Pharmaceuticals</i> , 2009, 2, 150-167.	1.7	43
51	Dimebon as a Potential Therapy for Alzheimer's Disease. <i>CNS Spectrums</i> , 2009, 14, 14-18.	0.7	11
52	Mitochondrial Cholesterol Loading Exacerbates Amyloid $\beta$ Peptide-Induced Inflammation and Neurotoxicity. <i>Journal of Neuroscience</i> , 2009, 29, 6394-6405.	1.7	134
53	Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. <i>Human Molecular Genetics</i> , 2009, 18, 3876-3893.	1.4	48
54	Nitric Oxide Biochemistry: Pathophysiology of Nitric Oxide-Mediated Protein Modifications. , 2009, , 29-44.		2
55	Cytoplasmic gelsolin increases mitochondrial activity and reduces A $\beta$ burden in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2009, 36, 42-50.	2.1	64

#	ARTICLE	IF	CITATIONS
56	Amyloid precursor protein, heat-shock proteins, and Bcl-2 form a complex in mitochondria and modulate mitochondria function and apoptosis in N2a cells. <i>Mechanisms of Ageing and Development</i> , 2009, 130, 592-601.	2.2	16
57	Mitochondrial accumulation of APP and A $\beta$ : significance for Alzheimer disease pathogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 4137-4145.	1.6	66
58	Mitochondria, cholesterol and amyloid $\beta$ peptide: a dangerous trio in Alzheimer disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 417-423.	1.0	50
59	Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 425-431.	1.0	159
60	Mitochondria and Alzheimer's disease: amyloid- $\beta$ peptide uptake and degradation by the presequence protease, hPreP. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 447-451.	1.0	44
61	The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 453-456.	1.0	40
62	Amino acids variations in Amyloid- $\beta$ peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 457-464.	1.0	30
63	The mitochondrial function was impaired in APP knockout mouse embryo fibroblast cells. <i>Science Bulletin</i> , 2009, 54, 1725-1731.	4.3	13
64	Protection against amyloid beta cytotoxicity by sulforaphane: Role of the proteasome. <i>Archives of Pharmacal Research</i> , 2009, 32, 109-115.	2.7	71
65	Amyloid- $\beta$ -Induced Ion Flux in Artificial Lipid Bilayers and Neuronal Cells: Resolving a Controversy. <i>Neurotoxicity Research</i> , 2009, 16, 1-13.	1.3	99
67	Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications†. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 1299-1315.	6.6	93
68	Neuroprotective Secreted Amyloid Precursor Protein Acts by Disrupting Amyloid Precursor Protein Dimers. <i>Journal of Biological Chemistry</i> , 2009, 284, 15016-15025.	1.6	118
69	The Alzheimer's disease mitochondrial cascade hypothesis: An update. <i>Experimental Neurology</i> , 2009, 218, 308-315.	2.0	181
70	Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. <i>Experimental Neurology</i> , 2009, 218, 286-292.	2.0	237
71	Heterogeneity of nervous system mitochondria: Location, location, location!. <i>Experimental Neurology</i> , 2009, 218, 293-307.	2.0	59
72	Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. <i>Genomics</i> , 2009, 93, 441-448.	1.3	123
73	Regional brain metabolism with cytochrome c oxidase histochemistry in a PS1/A246E mouse model of autosomal dominant Alzheimer's disease: Correlations with behavior and oxidative stress. <i>Neurochemistry International</i> , 2009, 55, 806-814.	1.9	36
74	Down-regulation of aminolevulinic acid synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 460, 180-184.	1.0	18

#	ARTICLE	IF	CITATIONS
75	Human and rodent amyloid- $\beta$ peptides differentially bind heme: Relevance to the human susceptibility to Alzheimer's disease. Archives of Biochemistry and Biophysics, 2009, 487, 59-65.	1.4	82
76	Prospective and retrospective memory in Alzheimer's disease and vascular dementia: Similar patterns of impairment. Journal of the Neurological Sciences, 2009, 283, 235-239.	0.3	22
78	Anatomically-distinct genetic associations of APOE $\epsilon$ 4 allele load with regional cortical atrophy in Alzheimer's disease. NeuroImage, 2009, 44, 724-728.	2.1	144
79	Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. Alzheimer's and Dementia, 2009, 5, 340-347.	0.4	96
80	The Neurodegenerative Mitochondriopathies. Journal of Alzheimer's Disease, 2009, 17, 737-751.	1.2	102
81	Role of Mitochondria in Neurodegenerative Diseases: Mitochondria as a Therapeutic Target in Alzheimer's Disease. CNS Spectrums, 2009, 14, 8-13.	0.7	155
82	Chapter 14. Ketone Bodies as a Therapeutic for Alzheimer's Disease. RSC Drug Discovery Series, 2010, , 275-306.	0.2	0
83	Alzheimer's disease: diagnostics, prognostics and the road to prevention. EPMA Journal, 2010, 1, 293-303.	3.3	36
84	Membrane Biophysics and Mechanics in Alzheimer's Disease. Molecular Neurobiology, 2010, 41, 138-148.	1.9	43
85	Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer's Disease—Therapeutic Aspects. Molecular Neurobiology, 2010, 41, 159-171.	1.9	222
86	The organellar peptidosome, PreP: A journey from Arabidopsis to Alzheimer's disease. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 1076-1080.	0.5	22
87	Kynurenines, neurodegeneration and Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2010, 14, 2045-2054.	1.6	57
88	APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 409-417.	1.1	62
89	The H63D HFE gene variant promotes activation of the intrinsic apoptotic pathway via mitochondria dysfunction following $\beta$ -amyloid peptide exposure. Journal of Neuroscience Research, 2010, 88, 3079-3089.	1.3	12
90	Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. Journal of Neurochemistry, 2010, 114, 1-12.	2.1	177
91	Mitochondrial biology in Alzheimer's disease pathogenesis. Journal of Neurochemistry, 2010, 114, 933-945.	2.1	66
92	A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics Journal, 2010, 10, 375-384.	0.9	351
93	Interaction of a novel mitochondrial protein, 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP1), with the amyloid precursor protein family. European Journal of Neuroscience, 2010, 31, 1926-1934.	1.2	15

#	ARTICLE	IF	CITATIONS
94	Mitochondrial preconditioning: a potential neuroprotective strategy. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	29
95	A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S401-S412.	1.2	141
96	Inhibitors of Catalase-Amyloid Interactions Protect Cells from $\beta^2$ -Amyloid-Induced Oxidative Stress and Toxicity. <i>Journal of Biological Chemistry</i> , 2010, 285, 38933-38943.	1.6	92
97	Substrate specificity of the TIM22 mitochondrial import pathway revealed with small molecule inhibitor of protein translocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9578-9583.	3.3	40
98	Is Alzheimer's Disease a Disorder of Mitochondria-Associated Membranes?. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S281-S292.	1.2	80
99	Gelsolin as therapeutic target in Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 585-592.	1.5	23
100	ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21146-21151.	3.3	155
101	An Inherited Variable Poly-T Repeat Genotype in TOMM40 in Alzheimer Disease. <i>Archives of Neurology</i> , 2010, 67, 536-41.	4.9	113
102	Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders. <i>Current Pharmaceutical Design</i> , 2010, 16, 2799-2817.	0.9	103
103	Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. <i>Brain</i> , 2010, 133, 3699-3723.	3.7	203
104	The Alzheimer's Disease Mitochondrial Cascade Hypothesis. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S265-S279.	1.2	435
105	Role of Mitochondrial Amyloid- $\beta^2$ in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S569-S578.	1.2	162
106	The consequences of mitochondrial amyloid $\beta^2$ -peptide in Alzheimer's disease. <i>Biochemical Journal</i> , 2010, 426, 255-270.	1.7	67
107	Potential Therapeutic Benefits of Strategies Directed to Mitochondria. <i>Antioxidants and Redox Signaling</i> , 2010, 13, 279-347.	2.5	162
108	A NH2 Tau Fragment Targets Neuronal Mitochondria at AD Synapses: Possible Implications for Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 445-470.	1.2	92
109	The Mitochondrial Secret(ase) of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S381-S400.	1.2	28
110	Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S439-S452.	1.2	112
111	Mitochondrial dysfunction: A potential link between neuroinflammation and neurodegeneration?. <i>Mitochondrion</i> , 2010, 10, 411-418.	1.6	201

#	ARTICLE	IF	CITATIONS
112	Association of Omi/HtrA2 with $\beta$ -secretase in mitochondria. <i>Neurochemistry International</i> , 2010, 57, 668-675.	1.9	33
113	Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 11-19.	1.8	127
114	Abnormal mitochondrial dynamics and neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 135-142.	1.8	229
115	Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 2-10.	1.8	587
116	$\beta$ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. <i>Neurobiology of Aging</i> , 2010, 31, 1569-1581.	1.5	63
117	Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort. <i>Neurobiology of Aging</i> , 2010, 31, 1355-1363.	1.5	97
118	Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. <i>Pharmaceuticals</i> , 2010, 3, 839-915.	1.7	179
119	Genetic variation at a single locus and age of onset for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2010, 6, 125-131.	0.4	90
120	Oxidative stress in Niemann-Pick disease, type C. <i>Molecular Genetics and Metabolism</i> , 2010, 101, 214-218.	0.5	113
121	Review Article: Genetics of Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 213-227.	1.2	748
122	Amyloid- $\beta$ and Mitochondria in Aging and Alzheimer's Disease: Implications for Synaptic Damage and Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S499-S512.	1.2	203
123	Mitochondria-Targeted Antioxidants Protect Against Amyloid- $\beta$ Toxicity in Alzheimer's Disease Neurons. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S609-S631.	1.2	404
124	Clinical Features and Pathogenesis of Alzheimer's Disease: Involvement of Mitochondria and Mitochondrial DNA. <i>Advances in Experimental Medicine and Biology</i> , 2010, 685, 34-44.	0.8	59
125	Diseases of DNA Repair. <i>Advances in Experimental Medicine and Biology</i> , 2010, . .	0.8	2
126	Mitochondrial Amyloid- $\beta$ Levels are Associated with the Extent of Mitochondrial Dysfunction in Different Brain Regions and the Degree of Cognitive Impairment in Alzheimer's Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S535-S550.	1.2	178
127	Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid- $\beta$ toxicity. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 15.	3.0	136
128	Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 21.	3.0	17
129	Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. <i>Human Molecular Genetics</i> , 2011, 20, 4515-4529.	1.4	522



#	ARTICLE	IF	CITATIONS
130	Decreased Proteolytic Activity of the Mitochondrial Amyloid- $\beta$ Degrading Enzyme, PreP Peptidasome, in Alzheimer's Disease Brain Mitochondria. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 75-87.	1.2	104
131	Metal attenuating therapies in neurodegenerative disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1717-1745.	1.4	22
132	Inhibition of Amyloid- $\beta$ (A $\beta$ ) Peptide-Binding Alcohol Dehydrogenase-A $\beta$ Interaction Reduces A $\beta$ Accumulation and Improves Mitochondrial Function in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 2313-2320.	1.7	170
133	Aging Promotes Amyloid- $\beta$ Peptide Induced Mitochondrial Dysfunctions in Rat Brain: A Molecular Link Between Aging and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 753-765.	1.2	8
134	The Interplay Between Mitochondrial Dynamics and Mitophagy. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 1939-1951.	2.5	632
135	Mitochondrial $\beta$ -secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. <i>FASEB Journal</i> , 2011, 25, 78-88.	0.2	104
136	Ubiquitin-dependent mitochondrial protein degradation. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1422-1426.	1.2	63
137	Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 507-513.	1.8	202
138	Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1182-1189.	1.8	47
139	Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: Implications for early intervention and therapeutics. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1359-1370.	1.8	252
140	Mitochondrial dysfunction and Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 320-330.	2.5	94
141	Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?. <i>Neuroscience</i> , 2011, 185, 135-149.	1.1	83
142	Redox Control of the Survival of Healthy and Diseased Cells. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2867-2908.	2.5	145
143	Amyloid-Beta Interaction with Mitochondria. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-12.	1.1	219
144	Enhanced Expression of the Voltage-Dependent Anion Channel 1 (VDAC1) in Alzheimer's Disease Transgenic Mice: An Insight into the Pathogenic Effects of Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2011, 23, 195-206.	1.2	105
145	Mitophagy in Neurodegeneration: An Opportunity for Therapy?. <i>Current Drug Targets</i> , 2011, 12, 790-799.	1.0	26
147	Mitochondrial $\beta$ -amyloid in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2011, 39, 868-873.	1.6	32
148	Association of N-Acetylaspartate and Cerebrospinal Fluid A $\beta$ 42 in Dementia. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 393-399.	1.2	10

#	ARTICLE	IF	CITATIONS
149	Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. <i>Journal of Pineal Research</i> , 2011, 51, 75-86.	3.4	147
150	Protein Degradation: BAGging Up the Trash. <i>Current Biology</i> , 2011, 21, R692-R695.	1.8	5
151	Hyperoside protects primary rat cortical neurons from neurotoxicity induced by amyloid $\beta$ -protein via the PI3K/Akt/Bad/BclXL-regulated mitochondrial apoptotic pathway. <i>European Journal of Pharmacology</i> , 2011, 672, 45-55.	1.7	125
152	Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD Mice. <i>Translational Neuroscience</i> , 2011, 2, 1-5.	0.7	20
153	Modes of $A\beta$ toxicity in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3359-3375.	2.4	78
154	Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression. <i>BMC Bioinformatics</i> , 2011, 12, S20.	1.2	46
155	Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. <i>Journal of Proteomics</i> , 2011, 74, 466-479.	1.2	113
156	Mitochondrial Mutations. <i>Neuroscientist</i> , 2011, 17, 645-658.	2.6	28
157	Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases. <i>Current Alzheimer Research</i> , 2011, 8, 393-409.	0.7	189
158	Therapeutic Approaches to Delay the Onset of Alzheimer's Disease. <i>Journal of Aging Research</i> , 2011, 1-11.	0.4	8
159	The Importance of Being Connected. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 247-251.	1.2	6
160	Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. <i>Human Molecular Genetics</i> , 2011, 20, 2495-2509.	1.4	644
161	Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2011, 286, 5215-5221.	1.6	155
162	Large-scale De Novo Prediction of Physical Protein-Protein Association. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M111.010629.	2.5	44
163	Mitochondria: The Common Upstream Driver of Amyloid and Tau Pathology in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2011, 8, 563-572.	0.7	69
164	Green Tea Epigallocatechin-3-Gallate (EGCG) and Other Flavonoids Reduce Alzheimer's Amyloid-Induced Mitochondrial Dysfunction. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 507-521.	1.2	156
165	Mitochondria-targeted catalase reduces abnormal APP processing, amyloid $\beta$ production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. <i>Human Molecular Genetics</i> , 2012, 21, 2973-2990.	1.4	156
166	No consistent evidence for association between mtDNA variants and Alzheimer disease. <i>Neurology</i> , 2012, 78, 1038-1042.	1.5	52

#	ARTICLE	IF	CITATIONS
168	Mitochondrial Dysfunction in Neurodegenerative Disease: Protein Aggregation, Autophagy, and Oxidative Stress. , 2012, , 95-111.		4
169	Are Retinoids a Promise for Alzheimer's Disease Management?. Current Medicinal Chemistry, 2012, 19, 6119-6125.	1.2	6
170	METABOLISM, AUTOPHAGY AND NEURODEGENERATION. , 2012, , 285-303.		0
171	Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects. Current Medicinal Chemistry, 2012, 19, 1899-1920.	1.2	53
172	Mitochondrial Oxidative Phosphorylation. Advances in Experimental Medicine and Biology, 2012, , .	0.8	10
173	New Insights in the Amyloid-Beta Interaction with Mitochondria. Journal of Aging Research, 2012, 2012, 1-9.	0.4	86
174	Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Human Molecular Genetics, 2012, 21, 5131-5146.	1.4	253
175	Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glia Metabolic Interaction and Neuro-metabolic Disorders. Current Neuropharmacology, 2012, 10, 393-403.	1.4	56
176	Antibodies Against the Tom40 Subunit of the Translocase of the Outer Mitochondrial Membrane Complex and Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 373-377.	1.2	6
177	Transcranial Electromagnetic Treatment Against Alzheimer's Disease: Why it has the Potential to Trump Alzheimer's Disease Drug Development. Journal of Alzheimer's Disease, 2012, 32, 243-266.	1.2	36
178	Decreased Accumulation of Subcellular Amyloid- $\beta$ with Improved Mitochondrial Function Mediates the Neuroprotective Effect of Huperzine A. Journal of Alzheimer's Disease, 2012, 31, 131-142.	1.2	45
179	Apoptosis is a Novel Pro-Apoptotic Protein and Mediates Cell Death in Neurodegeneration. Journal of Neuroscience, 2012, 32, 15565-15576.	1.7	58
180	Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer's Disease. Pharmaceuticals, 2012, 5, 1103-1119.	1.7	62
181	Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimer's and Dementia, 2012, 8, 490-495.	0.4	61
182	PI3K-ERK1/2 activation contributes to extracellular H <sub>2</sub> O <sub>2</sub> generation in amyloid $\beta$ toxicity. Neuroscience Letters, 2012, 526, 112-117.	1.0	15
183	Alzheimer disease as a vascular disorder: Where do mitochondria fit?. Experimental Gerontology, 2012, 47, 878-886.	1.2	30
184	Are oxidative stress and mitochondrial dysfunction the key players in the neurodegenerative diseases?. Free Radical Research, 2012, 46, 1327-1338.	1.5	97
185	TOMM40 rs10524523 Polymorphism's Role in Late-Onset Alzheimer's Disease and in Longevity. Journal of Alzheimer's Disease, 2012, 28, 309-322.	1.2	41

#	ARTICLE	IF	CITATIONS
186	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S405-S416.	1.2	73
187	Interaction between NH <sub>2</sub> -tau fragment and A $\beta$ <sup>2</sup> in Alzheimer's disease mitochondria contributes to the synaptic deterioration. <i>Neurobiology of Aging</i> , 2012, 33, 833.e1-833.e25.	1.5	78
188	Combined age- and trauma-related proteomic changes in rat neocortex: a basis for brain vulnerability. <i>Neurobiology of Aging</i> , 2012, 33, 1857-1873.	1.5	15
189	The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits. <i>Neurobiology of Aging</i> , 2012, 33, 1122.e1-1122.e10.	1.5	71
190	Relationship between genetic risk factors and markers for Alzheimer's disease pathology. <i>Biomarkers in Medicine</i> , 2012, 6, 477-495.	0.6	25
191	Swedish Alzheimer Mutation Induces Mitochondrial Dysfunction Mediated by HSP60 Mislocalization of Amyloid Precursor Protein (APP) and Beta-Amyloid. <i>Journal of Biological Chemistry</i> , 2012, 287, 30317-30327.	1.6	78
192	The therapeutic potential of mitochondrial channels in cancer, ischemia-reperfusion injury, and neurodegeneration. <i>Mitochondrion</i> , 2012, 12, 14-23.	1.6	28
193	Functionalized nanosystems for targeted mitochondrial delivery. <i>Mitochondrion</i> , 2012, 12, 190-201.	1.6	67
194	Plasticity of TOM complex assembly in skeletal muscle mitochondria in response to chronic contractile activity. <i>Mitochondrion</i> , 2012, 12, 305-312.	1.6	14
195	Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 639-649.	1.8	317
196	Mitochondrial respiratory chain dysfunction: Implications in neurodegeneration. <i>Free Radical Biology and Medicine</i> , 2012, 53, 595-609.	1.3	132
197	Mitochondria and Cell Bioenergetics: Increasingly Recognized Components and a Possible Etiologic Cause of Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1434-1455.	2.5	169
198	Mitochondria-Specific Accumulation of Amyloid $\beta$ <sup>2</sup> Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death. <i>PLoS ONE</i> , 2012, 7, e34929.	1.1	197
199	Mitochondrial Membrane Potential and Dynamics. , 2012, , 127-139.		1
200	Mitochondrion-Derived Reactive Oxygen Species Lead to Enhanced Amyloid Beta Formation. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1421-1433.	2.5	273
201	Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). <i>Behavioural Brain Research</i> , 2012, 234, 334-342.	1.2	118
202	Mitochondria and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 31-34.	0.3	35
203	Biology of Mitochondria in Neurodegenerative Diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 355-415.	0.9	141

#	ARTICLE	IF	CITATIONS
204	Mitochondria in Neurodegeneration. <i>Advances in Experimental Medicine and Biology</i> , 2012, 942, 269-286.	0.8	156
205	Altering Mitochondrial Dysfunction as an Approach to Treating Alzheimer's Disease. <i>Advances in Pharmacology</i> , 2012, 64, 155-176.	1.2	12
206	Synaptic Mitochondrial Pathology in Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1467-1475.	2.5	124
208	Advances in Mitochondrial Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2012, , .	0.8	17
209	Mitochondrial Genomic Analysis of Late Onset Alzheimer's Disease Reveals Protective Haplogroups H6A1A/H6A1B: The Cache County Study on Memory in Aging. <i>PLoS ONE</i> , 2012, 7, e45134.	1.1	44
210	HtrA Protease Family as Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2012, 19, 977-1009.	0.9	116
211	Overexpression of Human Wild-Type Amyloid- $\beta$ Protein Precursor Decreases the Iron Content and Increases the Oxidative Stress of Neuroblastoma SH-SY5Y Cells. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 523-530.	1.2	29
212	Promising Genetic Biomarkers of Preclinical Alzheimer's Disease: The Influence of <i>APOE</i> and <i>TOMM40</i> on Brain Integrity. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-15.	1.1	25
213	The Emerging Role of Proteolysis in Mitochondrial Quality Control and the Etiology of Parkinson's Disease. <i>Parkinson's Disease</i> , 2012, 2012, 1-16.	0.6	27
214	Mitochondrial diseases. <i>Lancet, The</i> , 2012, 379, 1825-1834.	6.3	411
215	Mitochondrial Importance in Alzheimer's, Huntington's and Parkinson's Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2012, 724, 205-221.	0.8	57
216	Cytochrome c Oxidase and Its Role in Neurodegeneration and Neuroprotection. <i>Advances in Experimental Medicine and Biology</i> , 2012, 748, 305-339.	0.8	54
217	Towards Alzheimer's root cause: ECSIT as an integrating hub between oxidative stress, inflammation and mitochondrial dysfunction. <i>BioEssays</i> , 2012, 34, 532-541.	1.2	43
218	Protective Effect of Isorhynchophylline Against $\beta$ -Amyloid-Induced Neurotoxicity in PC12 Cells. <i>Cellular and Molecular Neurobiology</i> , 2012, 32, 353-360.	1.7	86
219	Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. <i>Brain Research</i> , 2012, 1441, 64-78.	1.1	164
220	Mitochondrial dysfunction and accumulation of the $\beta$ -secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. <i>Neurobiology of Disease</i> , 2012, 45, 417-424.	2.1	118
221	Multifunctional roles of gelsolin in health and diseases. <i>Medicinal Research Reviews</i> , 2012, 32, 999-1025.	5.0	206
222	Mitochondrial DNA and inflammatory diseases. <i>Human Genetics</i> , 2012, 131, 161-173.	1.8	86

#	ARTICLE	IF	CITATIONS
223	Protective Effects of Hesperidin Against Amyloid- $\beta$ ( $A\beta$ ) Induced Neurotoxicity Through the Voltage Dependent Anion Channel 1 (VDAC1)-Mediated Mitochondrial Apoptotic Pathway in PC12 Cells. <i>Neurochemical Research</i> , 2013, 38, 1034-1044.	1.6	59
224	Metal dyshomeostasis and oxidative stress in Alzheimer's disease. <i>Neurochemistry International</i> , 2013, 62, 540-555.	1.9	376
225	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. <i>Progress in Neurobiology</i> , 2013, 108, 21-43.	2.8	499
226	Incorporation of $\beta$ -sitosterol into mitochondrial membrane enhances mitochondrial function by promoting inner mitochondrial membrane fluidity. <i>Journal of Bioenergetics and Biomembranes</i> , 2013, 45, 301-305.	1.0	48
227	Amyloid beta-induced glycogen synthase kinase 3 $\beta$ phosphorylated VDAC1 in Alzheimer's disease: Implications for synaptic dysfunction and neuronal damage. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 1913-1921.	1.8	114
228	Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. <i>Nature Genetics</i> , 2013, 45, 1249-1254.	9.4	117
229	Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation. <i>Neurobiology of Aging</i> , 2013, 34, 2399-2407.	1.5	38
230	Amyloid $\beta$ precursor protein as a molecular target for amyloid $\beta$ -induced neuronal degeneration in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2525-2537.	1.5	40
231	The Kunitz-protease inhibitor domain in amyloid precursor protein reduces cellular mitochondrial enzymes expression and function. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 642-647.	1.0	13
232	Epigenetic signature and enhancer activity of the human APOE gene. <i>Human Molecular Genetics</i> , 2013, 22, 5036-5047.	1.4	59
233	RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2368-2378.	1.8	32
234	$A\beta$ in Mitochondria—One Piece in the Alzheimer's Disease Puzzle. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2013, , 41-53.	0.4	0
235	Impaired mitochondrial energy production and ABC transporter function—A crucial interconnection in dementing proteopathies of the brain. <i>Mechanisms of Ageing and Development</i> , 2013, 134, 506-515.	2.2	26
236	Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 719-740.	1.2	40
237	The protective effect of hyperbaric oxygen and Ginkgo biloba extract on A $\beta$ -induced oxidative stress and neuronal apoptosis in rats. <i>Behavioural Brain Research</i> , 2013, 242, 1-8.	1.2	59
238	Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. <i>Neuromuscular Disorders</i> , 2013, 23, 969-974.	0.3	18
239	Structure-Based Design and Synthesis of Benzothiazole Phosphonate Analogues with Inhibitors of Human ABAD $\beta$ for Treatment of Alzheimer's Disease. <i>Chemical Biology and Drug Design</i> , 2013, 81, 238-249.	1.5	64
240	Mitochondrial Diseases of the Brain. <i>Free Radical Biology and Medicine</i> , 2013, 63, 1-29.	1.3	361

#	ARTICLE	IF	CITATIONS
241	Association of TOMM40 Polymorphisms with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population. <i>NeuroMolecular Medicine</i> , 2013, 15, 279-287.	1.8	29
242	Impaired transport of mitochondrial transcription factor A (TFAM) and the metabolic memory phenomenon associated with the progression of diabetic retinopathy. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 204-213.	1.7	36
243	Protein Truncation as a Common Denominator of Human Neurodegenerative Foldopathies. <i>Molecular Neurobiology</i> , 2013, 48, 516-532.	1.9	14
244	Protective Effect of Bajjiasu Against $\beta$ -Amyloid-Induced Neurotoxicity in PC12 Cells. <i>Cellular and Molecular Neurobiology</i> , 2013, 33, 837-850.	1.7	41
245	Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 67-75.	1.8	66
246	Axonal Transport and Mitochondrial Dysfunction in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2013, 12, 111-124.	0.8	32
247	Structural features within the nascent chain regulate alternative targeting of secretory proteins to mitochondria. <i>EMBO Journal</i> , 2013, 32, 1036-1051.	3.5	34
248	Dissection of Regulatory Networks that Are Altered in Disease via Differential Co-expression. <i>PLoS Computational Biology</i> , 2013, 9, e1002955.	1.5	164
250	Genetics of Alzheimer's Disease. <i>BioMed Research International</i> , 2013, 2013, 1-13.	0.9	75
251	Reduced VDAC1 Protects Against Alzheimer's Disease, Mitochondria, and Synaptic Deficiencies. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 679-690.	1.2	57
252	A Paradigm Shift for Evaluating Pharmacotherapy for Alzheimer's Disease: The 10-Patient Screening Protocol. <i>The Consultant Pharmacist</i> , 2013, 28, 443-454.	0.4	6
253	TOM40 Mediates Mitochondrial Dysfunction Induced by $\alpha$ -Synuclein Accumulation in Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e62277.	1.1	133
254	Alzheimer's Disease Susceptibility Genes APOE and TOMM40, and Hippocampal Volumes in the Lothian Birth Cohort 1936. <i>PLoS ONE</i> , 2013, 8, e80513.	1.1	29
255	The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 198.	1.0	33
256	Deconstructing Mitochondrial Dysfunction in Alzheimer Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-13.	1.9	98
257	Metabotyping of Docosahexaenoic Acid - Treated Alzheimer's Disease Cell Model. <i>PLoS ONE</i> , 2014, 9, e90123.	1.1	17
258	Proteomic Analysis of Lymphoblastoid Cells from Nasu-Hakola Patients: A Step Forward in Our Understanding of This Neurodegenerative Disorder. <i>PLoS ONE</i> , 2014, 9, e110073.	1.1	13
259	Mitochondrial Dysfunction: Different Routes to Alzheimer's Disease Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-11.	1.9	159

#	ARTICLE	IF	CITATIONS
260	Glutathione and mitochondria. <i>Frontiers in Pharmacology</i> , 2014, 5, 151.	1.6	401
261	Molecular docking of fisetin with AD associated AChE, ABAD and BACE1 proteins. <i>Bioinformation</i> , 2014, 10, 562-568.	0.2	41
262	Journal of Parkinson's disease & Alzheimer's disease. <i>Journal of Parkinson's Disease and Alzheimer's Disease</i> , 2014, 1, .	1.5	56
263	High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice. <i>Cell Death and Disease</i> , 2014, 5, e1083-e1083.	2.7	99
264	Altered synapses in a <i>Drosophila</i> model of Alzheimer's disease. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 373-85.	1.2	55
265	Effect of magnetic modulation of mitochondrial voltage-dependent anion channel 2 against beta-amyloid induced neurotoxicity. <i>RSC Advances</i> , 2014, 4, 63681-63684.	1.7	0
266	Mitochondrial protein quality control in health and disease. <i>British Journal of Pharmacology</i> , 2014, 171, 1870-1889.	2.7	51
267	Mitochondrial Dysfunction. <i>Progress in Molecular Biology and Translational Science</i> , 2014, 127, 183-210.	0.9	73
268	Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1739-1742.	0.8	4
269	The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1219-1231.	1.8	557
270	Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. <i>Developmental Biology</i> , 2014, 391, 230-240.	0.9	61
271	FLZ inhibited $\beta$ -secretase selectively and decreased $A\beta$ mitochondrial production in APP-SH-SY5Y cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 75-85.	1.4	9
272	Mitochondrial oxygen consumption deficits in skeletal muscle isolated from an Alzheimer's disease-relevant murine model. <i>BMC Neuroscience</i> , 2014, 15, 24.	0.8	25
273	The Protein Import Machinery of Mitochondria: A Regulatory Hub in Metabolism, Stress, and Disease. <i>Cell Metabolism</i> , 2014, 19, 357-372.	7.2	316
274	Mutations that affect mitochondrial functions and their association with neurodegenerative diseases. <i>Mutation Research - Reviews in Mutation Research</i> , 2014, 759, 1-13.	2.4	47
275	Down-regulation of Mortalin Exacerbates $A\beta$ -mediated Mitochondrial Fragmentation and Dysfunction. <i>Journal of Biological Chemistry</i> , 2014, 289, 2195-2204.	1.6	58
276	The role of amyloid-beta in the regulation of memory. <i>Biochemical Pharmacology</i> , 2014, 88, 479-485.	2.0	105
277	Synergistic Exacerbation of Mitochondrial and Synaptic Dysfunction and Resultant Learning and Memory Deficit in a Mouse Model of Diabetic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 451-463.	1.2	30



#	ARTICLE	IF	CITATIONS
278	Amyloid $\beta$ ( $A\beta^{42}$ ) induced paralysis in <i>C. elegans</i> is inhibited by the polyphenol quercetin through activation of protein degradation pathways. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 1931-1940.	1.5	113
279	Epoxyeicosatrienoic acids pretreatment improves amyloid $\beta$ -induced mitochondrial dysfunction in cultured rat hippocampal astrocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H475-H484.	1.5	55
280	Environmental factors in the development and progression of late-onset Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2014, 30, 253-270.	1.5	35
281	TOMM40 gene polymorphisms association with lipid profile. <i>Russian Journal of Genetics</i> , 2014, 50, 198-204.	0.2	4
282	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. <i>Neurobiology of Aging</i> , 2014, 35, 936.e5-936.e12.	1.5	47
283	New applications of disease genetics and pharmacogenetics to drug development. <i>Current Opinion in Pharmacology</i> , 2014, 14, 81-89.	1.7	56
284	Inhibition of mitochondrial protein import by mutant huntingtin. <i>Nature Neuroscience</i> , 2014, 17, 822-831.	7.1	184
285	Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. <i>Human Molecular Genetics</i> , 2014, 23, 3943-3957.	1.4	79
286	Upregulation of PGC-1 $\alpha$ expression by Alzheimer's disease-associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP. <i>Aging Cell</i> , 2014, 13, 263-272.	3.0	45
287	Mitochondrial Toxic Effects of $A\beta$ Through Mitofusins in the Early Pathogenesis of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2014, 50, 986-996.	1.9	32
288	Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. <i>Neurobiology of Aging</i> , 2014, 35, 1513.e25-1513.e33.	1.5	58
289	The Effect of TOMM40; Poly-T Repeat Lengths on Age of Onset and Cerebrospinal Fluid Biomarkers in Finnish Alzheimer's Disease Patients. <i>Neurodegenerative Diseases</i> , 2014, 14, 204-208.	0.8	6
291	Bivalent Compound 17MN Exerts Neuroprotection through Interaction at Multiple Sites in a Cellular Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1021-1033.	1.2	14
292	Structural Neuroimaging Genetics Interactions in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 1051-1063.	1.2	36
294	Melatonin regulates the autophagic flux via activation of $\alpha 7$ nicotinic acetylcholine receptors. <i>Journal of Pineal Research</i> , 2015, 59, 24-37.	3.4	38
296	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. , 2015, 6, 282.		101
297	How the Wnt signaling pathway protects from neurodegeneration: the mitochondrial scenario. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 166.	1.8	61
298	BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 382.	1.8	19

#	ARTICLE	IF	CITATIONS
299	Free Cholesterol – A Double-Edge Sword in Alzheimer Disease. , 0, , .		2
300	A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. <i>Frontiers in Pharmacology</i> , 2015, 6, 206.	1.6	109
301	$\beta$ -Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease. <i>Frontiers in Pharmacology</i> , 2015, 6, 221.	1.6	216
302	The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer’s Disease. <i>Current Alzheimer Research</i> , 2015, 12, 2-12.	0.7	8
303	Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-18.	1.9	486
304	Mitochondria-Targeted Protective Compounds in Parkinson’s and Alzheimer’s Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-30.	1.9	80
305	Biogenesis of mitochondrial outer membrane proteins, problems and diseases. <i>Biological Chemistry</i> , 2015, 396, 1199-1213.	1.2	24
306	Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. <i>Human Molecular Genetics</i> , 2015, 24, 2938-2951.	1.4	214
307	Oxidative stress accelerates amyloid deposition and memory impairment in a double-transgenic mouse model of Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 587, 126-131.	1.0	48
308	Identification of Alzheimer's disease-associated long noncoding RNAs. <i>Neurobiology of Aging</i> , 2015, 36, 2925-2931.	1.5	94
309	The Neuroprotective Effects of Decursin Isolated from <i>Angelica gigas</i> Nakai Against Amyloid $\beta$ -Protein-Induced Apoptosis in PC 12 Cells via a Mitochondria-Related Caspase Pathway. <i>Neurochemical Research</i> , 2015, 40, 1555-1562.	1.6	18
310	Protein carbonylation after traumatic brain injury: cell specificity, regional susceptibility, and gender differences. <i>Free Radical Biology and Medicine</i> , 2015, 78, 89-100.	1.3	47
311	The effect of TOMM40 on spatial navigation in amnesic mild cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, 2024-2033.	1.5	33
312	Synergistic effects of $\beta$ -amyloid and ceramide-induced insulin resistance on mitochondrial metabolism in neuronal cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1810-1823.	1.8	16
313	The Role of Oxidative Stress in Neurodegenerative Diseases. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2015, , 151-167.	0.4	2
314	Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins. <i>Cell Reports</i> , 2015, 11, 1134-1146.	2.9	88
315	Molecular mechanisms linking amyloid $\beta$ toxicity and Tau hyperphosphorylation in Alzheimer’s disease. <i>Free Radical Biology and Medicine</i> , 2015, 83, 186-191.	1.3	101
316	Mitochondrial biology, targets, and drug delivery. <i>Journal of Controlled Release</i> , 2015, 207, 40-58.	4.8	125

#	ARTICLE	IF	CITATIONS
317	Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin. <i>Human Molecular Genetics</i> , 2015, 24, 1350-1362.	1.4	20
318	Axonal Transport Defects in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 1309-1321.	1.9	75
319	Risk Factors for Alzheimer's Disease. , 2016, , .		1
320	Killing Me Softly: Connotations to Unfolded Protein Response and Oxidative Stress in Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	1.9	24
321	Alterations in Mitochondrial Quality Control in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 24.	1.8	153
322	The Rationale for Insulin Therapy in Alzheimer's Disease. <i>Molecules</i> , 2016, 21, 689.	1.7	14
323	Metabolic Characterization of Intact Cells Reveals Intracellular Amyloid Beta but Not Its Precursor Protein to Reduce Mitochondrial Respiration. <i>PLoS ONE</i> , 2016, 11, e0168157.	1.1	26
324	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. <i>Frontiers in Pharmacology</i> , 2016, 7, 88.	1.6	22
325	Physical Exercise and Brain Mitochondrial Fitness: The Possible Role Against Alzheimer's Disease. <i>Brain Pathology</i> , 2016, 26, 648-663.	2.1	73
326	Bioenergetics and metabolism: a bench to bedside perspective. <i>Journal of Neurochemistry</i> , 2016, 139, 126-135.	2.1	29
327	Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1257-1270.	1.2	22
328	Localization and Processing of the Amyloid- $\beta$ Protein Precursor in Mitochondria-Associated Membranes. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1549-1570.	1.2	107
329	Aberrant Co-localization of Synaptic Proteins Promoted by Alzheimer's Disease Amyloid- $\beta$ Peptides: Protective Effect of Human Serum Albumin. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 171-182.	1.2	18
330	Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 774-784.	2.6	56
331	Proteasome regulates turnover of toxic human amylin in pancreatic cells. <i>Biochemical Journal</i> , 2016, 473, 2655-2670.	1.7	18
332	Simultaneous evaluation of substrate-dependent oxygen consumption rates and mitochondrial membrane potential by TMRM and safranin in cortical mitochondria. <i>Bioscience Reports</i> , 2016, 36, e00286.	1.1	29
333	Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2016, 25, ddw330.	1.4	125
334	Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction. <i>Experimental Cell Research</i> , 2016, 347, 322-331.	1.2	84

#	ARTICLE	IF	CITATIONS
335	Tongluo Xingnao Effervescent Tablet preserves mitochondrial energy metabolism and attenuates cognition deficits in APP <sup>sw</sup> /PS1 <sup>De9</sup> mice. <i>Neuroscience Letters</i> , 2016, 630, 101-108.	1.0	5
336	Lost region in amyloid precursor protein (APP) through TALEN-mediated genome editing alters mitochondrial morphology. <i>Scientific Reports</i> , 2016, 6, 22244.	1.6	18
337	Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2016, 25, 4881-4897.	1.4	142
338	Mitochondrial Abnormalities and Synaptic Loss Underlie Memory Deficits Seen in Mouse Models of Obesity and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 915-932.	1.2	55
339	Alzheimer's disease: the role of mitochondrial dysfunction and potential new therapies. <i>Bioscience Horizons</i> , 2016, 9, .	0.6	15
340	Association Analysis of Polymorphisms in TOMM40, CR1, PVRL2, SORL1, PICALM, and 14q32.13 Regions in Colombian Alzheimer Disease Patients. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 305-309.	0.6	15
341	Combined Genome-Wide CSF A $\beta$ 42 Associations and Simple Network Properties Highlight New Risk Factors for Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 120-128.	1.1	11
342	Evolution of Alzheimer's disease pathogenesis conception. <i>Moscow University Biological Sciences Bulletin</i> , 2016, 71, 4-10.	0.1	4
343	Quantitative Proteomic Analysis of the Orbital Frontal Cortex in Rats Following Extended Exposure to Caffeine Reveals Extensive Changes to Protein Expression: Implications for Neurological Disease. <i>Journal of Proteome Research</i> , 2016, 15, 1455-1471.	1.8	8
344	Influence of metformin on mitochondrial subproteome in the brain of apoE knockout mice. <i>European Journal of Pharmacology</i> , 2016, 772, 99-107.	1.7	9
345	Association of common variants in TOMM40/APOE/APOC1 region with human longevity in a Chinese population. <i>Journal of Human Genetics</i> , 2016, 61, 323-328.	1.1	20
346	Hydrogen Sulfide Selectively Inhibits $\beta$ -Secretase Activity and Decreases Mitochondrial A $\beta$ Production in Neurons from APP/PS1 Transgenic Mice. <i>Neurochemical Research</i> , 2016, 41, 1145-1159.	1.6	8
347	Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 814-828.	1.8	124
348	Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets. <i>Journal of Neural Transmission</i> , 2016, 123, 125-135.	1.4	31
349	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. <i>Progress in Neurobiology</i> , 2017, 155, 171-193.	2.8	137
350	Mitochondrial Proteome Changes Correlating with $\beta$ -Amyloid Accumulation. <i>Molecular Neurobiology</i> , 2017, 54, 2060-2078.	1.9	17
351	Genome instability in Alzheimer disease. <i>Mechanisms of Ageing and Development</i> , 2017, 161, 83-94.	2.2	83
352	Mitochondrial genes are altered in blood early in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 53, 36-47.	1.5	132

#	ARTICLE	IF	CITATIONS
353	Comparison of the glycopattern alterations of mitochondrial proteins in cerebral cortex between rat Alzheimer's disease and the cerebral ischemia model. <i>Scientific Reports</i> , 2017, 7, 39948.	1.6	9
354	The <i>Alu</i> neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 828-838.	0.4	51
355	Mitochondria, Cybrids, Aging, and Alzheimer's Disease. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 146, 259-302.	0.9	87
356	Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!. <i>Handbook of Experimental Pharmacology</i> , 2017, 240, 281-308.	0.9	22
358	The protective role of plant biophenols in mechanisms of Alzheimer's disease. <i>Journal of Nutritional Biochemistry</i> , 2017, 47, 1-20.	1.9	71
359	Mitochondria-Division Inhibitor 1 Protects Against Amyloid- $\beta^2$ induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 147-162.	1.2	83
360	Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1087-1103.	1.2	176
361	Aqua-soluble DDQ reduces the levels of Drp1 and $A\beta^2$ and inhibits abnormal interactions between $A\beta^2$ and Drp1 and protects Alzheimer's disease neurons from $A\beta^2$ - and Drp1-induced mitochondrial and synaptic toxicities. <i>Human Molecular Genetics</i> , 2017, 26, 3375-3395.	1.4	50
362	Enhanced derivation of human pluripotent stem cell-derived cortical glutamatergic neurons by a small molecule. <i>Scientific Reports</i> , 2017, 7, 3282.	1.6	43
363	Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease. <i>Human Molecular Genetics</i> , 2017, 26, 1483-1496.	1.4	83
364	Mitochondrial Perturbation in Alzheimer's Disease and Diabetes. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 146, 341-361.	0.9	34
365	Long non-coding RNAs in brain development, synaptic biology, and Alzheimer's disease. <i>Brain Research Bulletin</i> , 2017, 132, 160-169.	1.4	52
366	Mitochondria are devoid of amyloid $\beta^2$ -protein ( $A\beta^2$ )-producing secretases: Evidence for unlikely occurrence within mitochondria of $A\beta^2$ generation from amyloid precursor protein. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 321-328.	1.0	23
367	Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 975-999.	1.2	294
368	PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. <i>Brain</i> , 2017, 140, 3233-3251.	3.7	211
369	Amyloid precursor protein drives down-regulation of mitochondrial oxidative phosphorylation independent of amyloid beta. <i>Scientific Reports</i> , 2017, 7, 9835.	1.6	31
370	Amyloid beta: structure, biology and structure-based therapeutic development. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1205-1235.	2.8	1,094
371	The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 2973-2986.	1.8	44

#	ARTICLE	IF	CITATIONS
372	Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases. <i>Journal of Cell Biology</i> , 2017, 216, 3917-3929.	2.3	59
373	Near infrared light decreases synaptic vulnerability to amyloid beta oligomers. <i>Scientific Reports</i> , 2017, 7, 15012.	1.6	38
374	Protein homeostasis of a metastable subproteome associated with Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5703-E5711.	3.3	77
375	Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia. <i>Acta Biochimica Et Biophysica Sinica</i> , 2017, 49, 83-89.	0.9	17
376	Mitochondrial Ca <sup>2+</sup> handling in Huntington's and Alzheimer's diseases – Role of ER-mitochondria crosstalk. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 1069-1077.	1.0	34
377	Amyloid precursor protein processing and bioenergetics. <i>Brain Research Bulletin</i> , 2017, 133, 71-79.	1.4	143
378	Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2017, 22, 605-614.	4.1	26
379	Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases. <i>Journal of Biomedical Science</i> , 2017, 24, 74.	2.6	86
380	Mitochondrial dynamics changes with age in an APPsw/PS1dE9 mouse model of Alzheimer's disease. <i>NeuroReport</i> , 2017, 28, 222-228.	0.6	40
381	Mitochondria as a Therapeutic Target for the Treatment of Alzheimer's Disease. , 2017, , 195-209.		0
382	Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , 2017, 11, 451.	1.4	139
383	Blood-Based Bioenergetic Profiling Reflects Differences in Brain Bioenergetics and Metabolism. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-9.	1.9	51
384	Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 797-810.	2.0	217
385	Warning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological disease. <i>Chromosome Research</i> , 2018, 26, 93-111.	1.0	55
386	Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 523-547.	1.2	75
387	A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease. <i>Cell Death and Disease</i> , 2018, 9, 335.	2.7	158
388	Spatio-temporal monitoring of lipid peroxyl radicals in live cell studies combining fluorogenic antioxidants and fluorescence microscopy methods. <i>Free Radical Biology and Medicine</i> , 2018, 128, 124-136.	1.3	19
389	Amyloid toxicity in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2018, 29, 613-627.	1.4	312

#	ARTICLE	IF	CITATIONS
390	A $\beta$ <sub>42</sub> oligomers impair the bioenergetic activity in hippocampal synaptosomes derived from APP-KO mice. <i>Biological Chemistry</i> , 2018, 399, 453-465.	1.2	2
391	Disturbed sleep and diabetes: A potential nexus of dementia risk. <i>Metabolism: Clinical and Experimental</i> , 2018, 84, 85-93.	1.5	37
392	Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1549-1565.	1.2	66
393	Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. <i>Alzheimer's and Dementia</i> , 2018, 14, 514-519.	0.4	14
394	TSPO regulation in reactive gliotic diseases. <i>Journal of Neuroscience Research</i> , 2018, 96, 978-988.	1.3	14
395	The APP <sup>swe</sup> /PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca <sup>2+</sup> dysregulation, and mitochondrial abnormalities. <i>Journal of Neurochemistry</i> , 2018, 145, 170-182.	2.1	4
396	Development of GMP-1, a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3464-3474.	1.6	11
397	Role of Mitochondria in Neurodegenerative Diseases: The Dark Side of the "Energy Factory", 2018, , 213-239.		6
398	Mitochondria and Alzheimer's Disease: the Role of Mitochondrial Genetic Variation. <i>Current Genetic Medicine Reports</i> , 2018, 6, 1-10.	1.9	45
399	Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer's disease: A focus on human studies. <i>Pharmacological Research</i> , 2018, 131, 32-43.	3.1	156
400	Exercise as a Positive Modulator of Brain Function. <i>Molecular Neurobiology</i> , 2018, 55, 3112-3130.	1.9	63
401	Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 34-53.	2.5	24
402	Neuroketotherapeutics: A modern review of a century-old therapy. <i>Neurochemistry International</i> , 2018, 117, 114-125.	1.9	96
403	Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission. <i>Neuroscience</i> , 2018, 370, 191-206.	1.1	48
404	Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1403-1416.	1.2	500
405	mPOS is a novel mitochondrial trigger of cell death " implications for neurodegeneration. <i>FEBS Letters</i> , 2018, 592, 759-775.	1.3	35
406	Nuclear Encoded Mitochondrial Proteins in Metabolite Transport and Oxidation Pathway Connecting Metabolism of Nutrients. , 2018, , .		0
407	Mitochondrial diseases caused by dysfunctional mitochondrial protein import. <i>Biochemical Society Transactions</i> , 2018, 46, 1225-1238.	1.6	25

#	ARTICLE	IF	CITATIONS
408	Age-Dependent Decrease of Mitochondrial Complex II Activity in a Familial Mouse Model for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 75-82.	1.2	13
409	Passive Immunotherapy in Alzheimer's Disease. , 0, , .		2
410	Análisis de desempeños cognitivos y polimorfismos en SORL1, PVRL2, CR1, TOMM40, APOE, PICALM, GWAS_14q, CLU y BIN1 en pacientes con trastorno neurocognitivo leve y en sujetos cognitivamente sanos. <i>Neurología</i> , 2021, 36, 681-691.	0.3	8
411	Mechanisms of protein toxicity in neurodegenerative diseases. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3159-3180.	2.4	103
412	Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases. <i>International Review of Cell and Molecular Biology</i> , 2018, 340, 209-344.	1.6	208
413	Current Concepts of Neurodegenerative Mechanisms in Alzheimer's Disease. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	113
414	Mitochondrial accumulation of amyloid $\beta$ (A $\beta$ ) peptides requires TOMM22 as a main A $\beta$ receptor in yeast. <i>Journal of Biological Chemistry</i> , 2018, 293, 12681-12689.	1.6	33
415	A novel high-throughput assay for respiration in isolated brain microvessels reveals impaired mitochondrial function in the aged mice. <i>GeroScience</i> , 2018, 40, 365-375.	2.1	54
416	Adapentronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 214.	1.8	13
417	Peptides as Potential Therapeutics for Alzheimer's Disease. <i>Molecules</i> , 2018, 23, 283.	1.7	45
418	DNA methylation in the APOE genomic region is associated with cognitive function in African Americans. <i>BMC Medical Genomics</i> , 2018, 11, 43.	0.7	32
419	MitoCPR: a novel protective mechanism in response to mitochondrial protein import stress. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 1072-1074.	0.9	5
420	Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. <i>Neuropsychopharmacology</i> , 2019, 44, 837-849.	2.8	142
421	The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells. <i>Scientific Reports</i> , 2019, 9, 11829.	1.6	48
422	The energetic brain "A review from students to students. <i>Journal of Neurochemistry</i> , 2019, 151, 139-165.	2.1	148
423	The Effects of APOE4 on Mitochondrial Dynamics and Proteins in vivo. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 861-875.	1.2	34
424	Mitochondrial degradation of amyloidogenic proteins "A new perspective for neurodegenerative diseases. <i>Progress in Neurobiology</i> , 2019, 181, 101660.	2.8	14
425	Integrating Gene and Protein Expression Reveals Perturbed Functional Networks in Alzheimer's Disease. <i>Cell Reports</i> , 2019, 28, 1103-1116.e4.	2.9	67



#	ARTICLE	IF	CITATIONS
426	Ginsenoside Re Inhibits ROS/ASK-1 Dependent Mitochondrial Apoptosis Pathway and Activation of Nrf2-Antioxidant Response in Beta-Amyloid-Challenged SH-SY5Y Cells. <i>Molecules</i> , 2019, 24, 2687.	1.7	52
427	Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update. <i>Frontiers in Pharmacology</i> , 2019, 10, 902.	1.6	173
428	Cognition in Vascular Aging and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 55-70.	1.2	8
429	Quantitative interaction proteomics reveals differences in the interactomes of amyloid precursor protein isoforms. <i>Journal of Neurochemistry</i> , 2019, 149, 399-412.	2.1	12
430	Quantitative profiling brain proteomes revealed mitochondrial dysfunction in Alzheimer's disease. <i>Molecular Brain</i> , 2019, 12, 8.	1.3	117
431	In vivo Ca <sup>2+</sup> imaging of astrocytic microdomains reveals a critical role of the amyloid precursor protein for mitochondria. <i>Glia</i> , 2019, 67, 985-998.	2.5	15
432	Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. <i>British Journal of Pharmacology</i> , 2019, 176, 3489-3507.	2.7	279
433	Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology. <i>Molecular Neurobiology</i> , 2019, 56, 8255-8276.	1.9	103
434	Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals?. <i>Journal of Alzheimer's Disease</i> , 2019, 72, S37-S58.	1.2	36
435	Interactions between BIM Protein and Beta-Amyloid May Reveal a Crucial Missing Link between Alzheimer's Disease and Neuronal Cell Death. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3555-3564.	1.7	21
436	The effects of bioactive components from the rhizome of <i>Salvia miltiorrhiza</i> (Danshen) on the characteristics of Alzheimer's disease. <i>Chinese Medicine</i> , 2019, 14, 19.	1.6	27
437	Mitochondrial Dysfunction and Stress Responses in Alzheimer's Disease. <i>Biology</i> , 2019, 8, 39.	1.3	40
438	Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats. <i>Neurochemistry International</i> , 2019, 128, 39-49.	1.9	46
439	Dysfunction of mitochondria: Implications for Alzheimer's disease. <i>International Review of Neurobiology</i> , 2019, 145, 13-27.	0.9	50
440	The vexing complexity of the amyloidogenic pathway. <i>Protein Science</i> , 2019, 28, 1177-1193.	3.1	25
441	PTCD1 Is Required for Mitochondrial Oxidative-Phosphorylation: Possible Genetic Association with Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2019, 39, 4636-4656.	1.7	26
442	Mitophagy inhibits amyloid- $\beta^2$ and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. <i>Nature Neuroscience</i> , 2019, 22, 401-412.	7.1	1,008
443	A promising structural magnetic resonance imaging assessment in patients with preclinical cognitive decline and diabetes mellitus. <i>Journal of Cellular Physiology</i> , 2019, 234, 16838-16846.	2.0	5

#	ARTICLE	IF	CITATIONS
444	Evolving paradigms on the interplay of mitochondrial Hsp70 chaperone system in cell survival and senescence. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2019, 54, 517-536.	2.3	16
445	Clogging the mitochondrial protein-entry gate promotes obesity. <i>Nature Metabolism</i> , 2019, 1, 1175-1176.	5.1	1
446	Mitochondrial Cholesterol in Alzheimer's Disease and Niemann-Pick Type C Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1168.	1.1	37
447	Dysregulation of amyloid precursor protein impairs adipose tissue mitochondrial function and promotes obesity. <i>Nature Metabolism</i> , 2019, 1, 1243-1257.	5.1	39
448	Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2019, 176, 3464-3474.	2.7	28
449	Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a magnetic resonance spectroscopy study at 7T. <i>Neurobiology of Aging</i> , 2019, 73, 211-218.	1.5	61
450	Underappreciated Roles of the Translocase of the Outer and Inner Mitochondrial Membrane Protein Complexes in Human Disease. <i>DNA and Cell Biology</i> , 2019, 38, 23-40.	0.9	21
451	Biochemical deficits and cognitive decline in brain aging: Intervention by dietary supplements. <i>Journal of Chemical Neuroanatomy</i> , 2019, 95, 70-80.	1.0	39
452	Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration. <i>Cellular and Molecular Neurobiology</i> , 2020, 40, 313-345.	1.7	11
453	Mitophagy in Alzheimer's Disease and Other Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 150.	1.8	151
454	Metal Binding by GMP-1 and Its Pyrimido [1, 2]benzimidazole Analogs Confirms Protection Against Amyloid- $\beta^2$ Associated Neurotoxicity. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 695-705.	1.2	7
455	Inhibition of DNMT1 and mitochondrial fission attenuates inflammatory response in fibroblast-like synoviocytes of rheumatoid arthritis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1516-1528.	1.6	22
456	Analysis of cognitive performance and polymorphisms of SORL1, PVRL2, CR1, TOMM40, APOE, PICALM, GWAS_14q, CLU, and BIN1 in patients with mild cognitive impairment and cognitively healthy controls. <i>Neurologia (English Edition)</i> , 2021, 36, 681-691.	0.2	7
457	Corticotropin-releasing hormone (CRH) alters mitochondrial morphology and function by activating the NF- $\kappa$ B-DRP1 axis in hippocampal neurons. <i>Cell Death and Disease</i> , 2020, 11, 1004.	2.7	16
458	Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer's Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S359-S378.	1.2	10
459	Spotlight on Ferroptosis: Iron-Dependent Cell Death in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 196.	1.7	47
460	The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease. <i>International Review of Neurobiology</i> , 2020, 154, 207-233.	0.9	43
461	Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration. <i>Antioxidants</i> , 2020, 9, 647.	2.2	159

#	ARTICLE	IF	CITATIONS
462	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. <i>Journal of Personalized Medicine</i> , 2020, 10, 116.	1.1	26
463	When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. <i>Antioxidants</i> , 2020, 9, 740.	2.2	52
464	Molecular Dysfunctions of Mitochondria-Associated Membranes (MAMs) in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9521.	1.8	34
465	Targeting Mitophagy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1273-1297.	1.2	6
466	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. <i>Biomarker Insights</i> , 2020, 15, 117727192097636.	1.0	21
467	Extracellular Vesicles and Damage-Associated Molecular Patterns: A Pandora's Box in Health and Disease. <i>Frontiers in Immunology</i> , 2020, 11, 601740.	2.2	32
468	Common aspects between glaucoma and brain neurodegeneration. <i>Mutation Research - Reviews in Mutation Research</i> , 2020, 786, 108323.	2.4	8
469	Infusion of Plasma from Exercised Mice Ameliorates Cognitive Dysfunction by Increasing Hippocampal Neuroplasticity and Mitochondrial Functions in 3xTg-AD Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3291.	1.8	13
470	Intramitochondrial proteostasis is directly coupled to $\alpha$ -synuclein and amyloid $\beta$ 1-42 pathologies. <i>Journal of Biological Chemistry</i> , 2020, 295, 10138-10152.	1.6	22
471	Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. <i>Molecular Neurodegeneration</i> , 2020, 15, 30.	4.4	562
472	The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence. <i>BioMed Research International</i> , 2020, 2020, 1-18.	0.9	31
473	Mechanisms Linking Mitochondrial Dysfunction and Proteostasis Failure. <i>Trends in Cell Biology</i> , 2020, 30, 317-328.	3.6	27
474	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 1188-1236.	2.5	61
475	Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from $A\beta$ -mediated oxidative and metabolic damage. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 13.	3.0	42
476	Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 1444.	1.4	55
477	How the Mitoprotein-Induced Stress Response Safeguards the Cytosol: A Unified View. <i>Trends in Cell Biology</i> , 2020, 30, 241-254.	3.6	66
478	Influence of Mitochondrial ATP-Sensitive Potassium Channels on Toxic Effect of Amyloid- $\beta$ 25-35. <i>Neurochemical Journal</i> , 2020, 14, 90-100.	0.2	1
479	Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. <i>Experimental Neurology</i> , 2020, 330, 113321.	2.0	66

#	ARTICLE	IF	CITATIONS
480	Mitochondrial and Nuclear DNA Oxidative Damage in Physiological and Pathological Aging. <i>DNA and Cell Biology</i> , 2020, 39, 1410-1420.	0.9	69
481	Effects of Novel Tacrine Derivatives on Mitochondrial Energy Metabolism and Monoamine Oxidase Activityâ€”In Vitro Study. <i>Molecular Neurobiology</i> , 2021, 58, 1102-1113.	1.9	5
482	Mitochondria and Calcium in Alzheimerâ€™s Disease: From Cell Signaling to Neuronal Cell Death. <i>Trends in Neurosciences</i> , 2021, 44, 136-151.	4.2	119
483	Alzheimerâ€™s disease improved through the activity of mitochondrial chain complexes and their gene expression in rats by boswellic acid. <i>Metabolic Brain Disease</i> , 2021, 36, 255-264.	1.4	17
484	Quality control of the mitochondrial proteome. <i>Nature Reviews Molecular Cell Biology</i> , 2021, 22, 54-70.	16.1	231
485	Functions of amyloid precursor protein in metabolic diseases. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154454.	1.5	38
486	Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2021, 421, 117253.	0.3	95
487	Mitochondrial Protein Import Dysfunction in Pathogenesis of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2021, 58, 1418-1437.	1.9	11
488	Exploring the role of mitochondrial proteins as molecular target in Alzheimerâ€™s disease. <i>Mitochondrion</i> , 2021, 56, 62-72.	1.6	15
489	Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders. , 2021, 221, 107749.		29
490	Mitochondrial protein import dysfunction: mitochondrial disease, neurodegenerative disease and cancer. <i>FEBS Letters</i> , 2021, 595, 1107-1131.	1.3	48
491	Alterations in inter-organelle crosstalk and Ca <sup>2+</sup> signaling through mitochondria during proteotoxic stresses. <i>Mitochondrion</i> , 2021, 57, 37-46.	1.6	10
492	Intracellular Sources of ROS/H <sub>2</sub> O <sub>2</sub> in Health and Neurodegeneration: Spotlight on Endoplasmic Reticulum. <i>Cells</i> , 2021, 10, 233.	1.8	49
493	Impact of Genetic Risk Factors for Alzheimerâ€™s Disease on Brain Glucose Metabolism. <i>Molecular Neurobiology</i> , 2021, 58, 2608-2619.	1.9	13
494	Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimerâ€™s disease. <i>Clinical Science</i> , 2021, 135, 109-126.	1.8	32
495	Novel DNA methylation marker discovery by assumptionâ€”free genomeâ€”wide association analysis of cognitive function in twins. <i>Aging Cell</i> , 2021, 20, e13293.	3.0	7
496	Metabolic disorder in Alzheimerâ€™s disease. <i>Metabolic Brain Disease</i> , 2021, 36, 781-813.	1.4	23
497	Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 646901.	1.7	16

#	ARTICLE	IF	CITATIONS
498	In search of biomarkers for leprosy by unraveling the host immune response to <i>Mycobacterium leprae</i> . <i>Immunological Reviews</i> , 2021, 301, 175-192.	2.8	33
499	The role of mitophagy in the regulation of mitochondrial energetic status in neurons. <i>Autophagy</i> , 2021, 17, 4182-4201.	4.3	61
500	Current Perspective of Hydrogen Sulfide as a Novel Gaseous Modulator of Oxidative Stress in Glaucoma. <i>Antioxidants</i> , 2021, 10, 671.	2.2	7
501	Mitochondrial Dysfunction and Mitophagy Closely Cooperate in Neurological Deficits Associated with Alzheimer's Disease and Type 2 Diabetes. <i>Molecular Neurobiology</i> , 2021, 58, 3677-3691.	1.9	16
502	Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics. <i>Metabolites</i> , 2021, 11, 233.	1.3	10
503	NIPSNAP protein family emerges as a sensor of mitochondrial health. <i>BioEssays</i> , 2021, 43, e2100014.	1.2	10
504	Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. <i>Cells</i> , 2021, 10, 1236.	1.8	73
505	In vivo brain imaging of mitochondrial Ca <sup>2+</sup> in neurodegenerative diseases with multiphoton microscopy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118998.	1.9	8
507	Interplay between Mitochondrial Protein Import and Respiratory Complexes Assembly in Neuronal Health and Degeneration. <i>Life</i> , 2021, 11, 432.	1.1	14
508	Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration. <i>Cells</i> , 2021, 10, 1174.	1.8	3
509	Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 625-642.	1.4	19
510	Immature Persimmon Suppresses Amyloid Beta (A $\beta$ ) Mediated Cognitive Dysfunction via Tau Pathology in ICR Mice. <i>Current Issues in Molecular Biology</i> , 2021, 43, 405-422.	1.0	2
511	Alzheimer's disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links. <i>World Journal of Diabetes</i> , 2021, 12, 745-766.	1.3	28
512	TOMM40 RNA Transcription in Alzheimer's Disease Brain and Its Implication in Mitochondrial Dysfunction. <i>Genes</i> , 2021, 12, 871.	1.0	17
513	Targeting cellular batteries for the therapy of neurological diseases. <i>Environmental Science and Pollution Research</i> , 2021, 28, 41517-41532.	2.7	3
514	Mitochondrial genetic variation in human bioenergetics, adaptation, and adult disease. <i>American Journal of Human Biology</i> , 2021, , e23629.	0.8	1
515	Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 511-531.	5.7	26
516	Sensing, signaling and surviving mitochondrial stress. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5925-5951.	2.4	40

#	ARTICLE	IF	CITATIONS
517	Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 1069.	2.2	53
518	The transferred translocases: An old wine in a new bottle. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 1587-1610.	1.4	1
519	Linking Oxidative Stress and Proteinopathy in Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 1231.	2.2	57
520	Bibliometric Analysis Study on the Mechanisms of Brain Energy Metabolism Disorders in Alzheimer's Disease From 2000 to 2020. <i>Frontiers in Neurology</i> , 2021, 12, 670220.	1.1	15
521	Neuroprotective Efficacy of Apple Cider Vinegar on Zinc-High Fat Diet-Induced Mono Amine Oxidase Alteration in Murine Model of AD. <i>Journal of the American College of Nutrition</i> , 2022, 41, 658-667.	1.1	8
522	Structural and Functional Alterations in Mitochondria-Associated Membranes (MAMs) and in Mitochondria Activate Stress Response Mechanisms in an In Vitro Model of Alzheimer's Disease. <i>Biomedicines</i> , 2021, 9, 881.	1.4	26
523	Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies—A Non-Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7366.	1.8	15
524	Mitochondrial pathway polygenic risk scores are associated with Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2021, 108, 213-222.	1.5	10
525	Defective mitophagy and synaptic degeneration in Alzheimer's disease: Focus on aging, mitochondria and synapse. <i>Free Radical Biology and Medicine</i> , 2021, 172, 652-667.	1.3	81
526	Targeted Lipidomics of Mitochondria in a Cellular Alzheimer's Disease Model. <i>Biomedicines</i> , 2021, 9, 1062.	1.4	9
527	Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium. <i>Neuroscience Letters</i> , 2021, 760, 136078.	1.0	10
528	Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease. <i>Pharmacological Research</i> , 2021, 171, 105783.	3.1	32
529	Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials. <i>Journal of Neuroscience Research</i> , 2021, 99, 2888-2905.	1.3	9
530	The transcriptional landscape of Alzheimer's disease and its association with Wnt signaling pathway. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 454-466.	2.9	8
531	Molecular Machinery and Pathophysiology of Mitochondrial Dynamics. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743892.	1.8	18
532	Mitochondrial links between brain aging and Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 33.	3.6	26
533	Two hit mitochondrial-driven model of synapse loss in neurodegeneration. <i>Neurobiology of Disease</i> , 2021, 158, 105451.	2.1	10
534	Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102422.	1.7	11

#	ARTICLE	IF	CITATIONS
535	Defective Autophagy and Mitophagy in Aging and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 612757.	1.4	85
536	Targeting Alzheimer's disease neuronal mitochondria as a therapeutic approach. , 2021, , 343-364.		0
537	Aging-Dependent Mitophagy Dysfunction in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 2362-2378.	1.9	25
538	Association and Interaction of TOMM40 and PVRL2 with Plasma Amyloid- $\beta$ and Alzheimer's Disease Among Chinese Older Adults: A Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
540	A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1131, 131-161.	0.8	39
541	The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 2959-2980.	1.9	180
542	Roles of mitochondria in human disease. <i>Essays in Biochemistry</i> , 2010, 47, 115-137.	2.1	147
543	Mitochondrial Mutations: Newly Discovered Players in Neuronal Degeneration. <i>Neuroscientist</i> , 2011, 17, 645-658.	2.6	24
544	Physical exercise during exposure to 40-Hz light flicker improves cognitive functions in the 3xTg mouse model of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 62.	3.0	33
545	Mitochondrial Complex I Inhibition Accelerates Amyloid Toxicity. <i>Development &amp; Reproduction</i> , 2017, 21, 417-424.	0.1	13
546	The Dictyostelium model for mitochondrial biology and disease. <i>International Journal of Developmental Biology</i> , 2019, 63, 497-508.	0.3	18
547	Relationships between Mitochondrial Dysfunction and Neurotransmission Failure in Alzheimer's Disease. , 2020, 11, 1291.		64
548	Mitochondrial cholesterol in health and disease. <i>Histology and Histopathology</i> , 2009, 24, 117-32.	0.5	79
549	Brain pyrimidine nucleotide synthesis and Alzheimer disease. <i>Aging</i> , 2019, 11, 8433-8462.	1.4	23
550	Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients. <i>Oncotarget</i> , 2018, 9, 35207-35225.	0.8	32
551	Key Role of Mitochondria in Alzheimer's Disease Synaptic Dysfunction. <i>Current Pharmaceutical Design</i> , 2013, 19, 6440-6450.	0.9	41
552	New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders. <i>Current Pharmaceutical Design</i> , 2017, 23, 731-752.	0.9	30
553	Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders. <i>Current Alzheimer Research</i> , 2020, 17, 238-258.	0.7	5

#	ARTICLE	IF	CITATIONS
554	Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glia Metabolic Interaction and Neuro-metabolic Disorders. <i>Current Neuropharmacology</i> , 2012, 10, 393-403.	1.4	39
555	Mechanisms of Melatonin in Alleviating Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2017, 15, 1010-1031.	1.4	140
556	Therapeutic Potential of Multifunctional Tacrine Analogues. <i>Current Neuropharmacology</i> , 2019, 17, 472-490.	1.4	35
557	Potential Therapeutic Role of Phytochemicals to Mitigate Mitochondrial Dysfunctions in Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 23.	2.2	25
558	Recent Progress of Mitochondrial Dysfunction Induced by $\beta$ -Amyloid Protein*. <i>Progress in Biochemistry and Biophysics</i> , 2010, 37, 589-593.	0.3	3
559	Metal Metabolic Homeostasis Disruption and Early Initiation of Mechanism for Alzheimer's Disease*. <i>Progress in Biochemistry and Biophysics</i> , 2012, 39, 756-763.	0.3	4
560	Mitochondrial Dysregulation in Skeletal Muscle from Patients Diagnosed with Alzheimer's Disease and Sporadic Inclusion Body Myositis. <i>Open Journal of Molecular and Integrative Physiology</i> , 2014, 04, 11-19.	0.6	5
561	Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. <i>World Journal of Diabetes</i> , 2015, 6, 1223.	1.3	35
562	The role of cell type-specific mitochondrial dysfunction in the pathogenesis of Alzheimer's disease. <i>BMB Reports</i> , 2019, 52, 679-688.	1.1	19
563	Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer's disease. <i>BMB Reports</i> , 2020, 53, 35-46.	1.1	44
564	Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. <i>ELife</i> , 2016, 5, .	2.8	117
565	Unfolding is the driving force for mitochondrial import and degradation of the Parkinson's disease-related protein DJ-1. <i>Journal of Cell Science</i> , 2021, 134, .	1.2	3
566	Synaptic Mitochondria: An Early Target of Amyloid- $\beta$ and Tau in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1391-1414.	1.2	26
567	Research on The Effect of Amyloid beta on Mitochondrial Dysfunction & In vivo and & In vitro*. <i>Progress in Biochemistry and Biophysics</i> , 2010, 37, 154-160.	0.3	1
568	The Genetics of Alzheimer's Disease and Parkinson's Disease. <i>Advances in Neurobiology</i> , 2011, , 695-755.	1.3	7
570	mtDNA Mutations in Brain Aging and Neurodegeneration. , 2012, , 79-91.		0
572	Consequences of Altered Mortalin Expression in Control of Cell Proliferation and Brain Function. , 2012, , 95-109.		0
573	Mitochondrial Dysfunction in Sporadic Alzheimer's Disease: Mechanisms, Consequences and Interventions. , 2012, , 49-65.		0



#	ARTICLE	IF	CITATIONS
574	The Amyloid $\beta$ -Protein and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2012, , 1-85.	0.0	0
575	The Impact of HAART on Advanced Brain Aging: Implications for Mitochondrial Dysfunction and APP Processing. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2013, 05, .	0.1	1
576	Genetic and non-genetic factors responsible for mitochondrial failure and Alzheimer's disease. <i>Genetika</i> , 2014, 46, 631-647.	0.1	0
579	Mitochondrial Function and Neurodegenerative Diseases. , 2018, , 369-414.		1
581	Alternation of Mitochondrial and Golgi Apparatus in Neurodegenerative Disorders. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2019, , 102-128.	0.1	0
582	Mitochondrial Dysfunction in Aging and Neurodegeneration. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2019, , 76-101.	0.1	0
584	Disentangling Mitochondria in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11520.	1.8	34
585	Microglial Mitophagy and Neurodegenerative Disorders. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2020, , 88-128.	0.1	0
586	Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. <i>Molecular Neurodegeneration</i> , 2021, 16, 75.	4.4	44
588	Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. <i>Acta Naturae</i> , 2020, 12, 60-80.	1.7	3
590	Pathogenesis of Alzheimer's disease. <i>Clinical Interventions in Aging</i> , 2007, 2, 347-59.	1.3	162
592	Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 570-81.	0.5	75
596	Contribution of Mitochondrial Dysfunction Combined with NLRP3 Inflammasome Activation in Selected Neurodegenerative Diseases. <i>Pharmaceuticals</i> , 2021, 14, 1221.	1.7	13
597	Mitochondrial Quality Control Strategies: Potential Therapeutic Targets for Neurodegenerative Diseases?. <i>Frontiers in Neuroscience</i> , 2021, 15, 746873.	1.4	17
598	Alteration of mitochondrial homeostasis is an early event in a <i>C. elegans</i> model of human tauopathy. <i>Aging</i> , 2021, 13, 23876-23894.	1.4	9
599	Exercise and <i>Syzygium aromaticum</i> reverse memory deficits, apoptosis and mitochondrial dysfunction of the hippocampus in Alzheimer's disease. <i>Journal of Ethnopharmacology</i> , 2022, 286, 114871.	2.0	11
600	Mitochondrial Membrane Potential Influences Amyloid- $\beta$ Protein Precursor Localization and Amyloid- $\beta$ Secretion. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 381-394.	1.2	16
601	Mitochondrially-Targeted Therapeutic Strategies for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021, 18, 753-771.	0.7	6

#	ARTICLE	IF	CITATIONS
602	The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress. , 2022, 13, 37.		22
603	A Levee to the Flood: Pre-injury Neuroinflammation and Immune Stress Influence Traumatic Brain Injury Outcome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 788055.	1.7	3
604	Association and interaction of TOMM40 and PVRL2 with plasma amyloid- $\beta^2$ and Alzheimer's disease among Chinese older adults: a population-based study. <i>Neurobiology of Aging</i> , 2022, 113, 143-151.	1.5	12
605	Beta-Amyloid Instigates Dysfunction of Mitochondria in Cardiac Cells. <i>Cells</i> , 2022, 11, 373.	1.8	15
606	Western and ketogenic diets in neurological disorders: can you tell the difference?. <i>Nutrition Reviews</i> , 2022, 80, 1927-1941.	2.6	7
607	The 40-Hz White Light-Emitting Diode (LED) Improves the Structure-Function of the Brain Mitochondrial KATP Channel and Respiratory Chain Activities in Amyloid Beta Toxicity. <i>Molecular Neurobiology</i> , 2022, 59, 2424-2440.	1.9	5
608	Physiology and pharmacology of amyloid precursor protein. , 2022, 235, 108122.		33
609	The amyloid state of proteins: A boon or bane?. <i>International Journal of Biological Macromolecules</i> , 2022, 200, 593-617.	3.6	12
610	MicroRNA-4722-5p and microRNA-615-3p serve as potential biomarkers for Alzheimer's disease. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 241.	0.8	14
611	Exercise-Eating Pattern and Social Inclusion (EES) is an Effective Modulator of Pathophysiological Hallmarks of Alzheimer's Disease. , 0, , .		0
612	Mitochondrial Targeting of Amyloid- $\beta^2$ Protein Precursor Intracellular Domain Induces Hippocampal Cell Death via a Mechanism Distinct from Amyloid- $\beta^2$ . <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1727-1744.	1.2	5
613	N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases. <i>Antioxidants</i> , 2022, 11, 416.	2.2	10
614	From the Structural and (Dys)Function of ATP Synthase to Deficiency in Age-Related Diseases. <i>Life</i> , 2022, 12, 401.	1.1	11
615	Endoplasmic reticulum-unfolded protein response pathway modulates the cellular response to mitochondrial proteotoxic stress. <i>Cell Stress and Chaperones</i> , 2022, 27, 241-256.	1.2	9
617	The key roles of organelles and ferroptosis in Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2022, 100, 1257-1280.	1.3	9
618	Verteporfin is a substrate-selective $\beta^3$ -secretase inhibitor that binds the amyloid precursor protein transmembrane domain. <i>Journal of Biological Chemistry</i> , 2022, 298, 101792.	1.6	3
619	Cytosolic Quality Control of Mitochondrial Protein Precursors-The Early Stages of the Organelle Biogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7.	1.8	10
620	Role of Mitochondrial Protein Import in Age-Related Neurodegenerative and Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 3528.	1.8	8

#	ARTICLE	IF	CITATIONS
621	Mitochondrial Deficits With Neural and Social Damage in Early-Stage Alzheimer's Disease Model Mice. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748388.	1.7	7
622	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 858429.	1.7	9
624	Mitochondrial Dysfunction in Aging and Neurodegeneration. , 2022, , 253-278.		0
625	Altered Mitochondrial Protein Homeostasis and Proteinopathies. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 867935.	1.4	8
626	Natural Bioactive Products and Alzheimer's Disease Pathology: Lessons from <i>Caenorhabditis elegans</i> Transgenic Models. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 28.	1.0	4
627	Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-28.	1.9	16
628	The Molecular and Functional Interaction Between Membrane-Bound Organelles and Membrane-Less Condensates. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 896305.	1.8	4
629	Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation. <i>Journal of Biological Chemistry</i> , 2022, 298, 102062.	1.6	30
630	Intracellular A $\beta$ 242 Aggregation Leads to Cellular Thermogenesis. <i>Journal of the American Chemical Society</i> , 2022, 144, 10034-10041.	6.6	16
631	Defective mitophagy and the etiopathogenesis of Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	11
632	Boosting mitochondrial health to counteract neurodegeneration. <i>Progress in Neurobiology</i> , 2022, 215, 102289.	2.8	15
633	Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 1039-1056.	0.8	1
634	Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	7
635	Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs. <i>Frontiers in Aging</i> , 0, 3, .	1.2	3
636	Targeting the alternative oxidase (AOX) for human health and food security, a pharmaceutical and agrochemical target or a rescue mechanism?. <i>Biochemical Journal</i> , 2022, 479, 1337-1359.	1.7	6
637	Neuroprotective Effects of Oligosaccharides in <i>Rehmanniae Radix</i> on Transgenic <i>Caenorhabditis elegans</i> Models for Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
638	Spatial Distribution and Hierarchical Clustering of $\beta$ -Amyloid and Glucose Metabolism in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
639	Dysfunction of Mitochondria in Alzheimer's Disease: ANT and VDAC Interact with Toxic Proteins and Aid to Determine the Fate of Brain Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7722.	1.8	14

#	ARTICLE	IF	CITATIONS
640	mtDNA Maintenance and Alterations in the Pathogenesis of Neurodegenerative Diseases. <i>Current Neuropharmacology</i> , 2023, 21, 578-598.	1.4	1
641	Neuronopathic Gaucher disease: Beyond lysosomal dysfunction. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	6
642	Adult-Onset Deficiency of Mitochondrial Complex III in a Mouse Model of Alzheimer's Disease Decreases Amyloid Beta Plaque Formation. <i>Molecular Neurobiology</i> , 0, , .	1.9	2
643	Molecular linkages among A $\beta$ , tau, impaired mitophagy, and mitochondrial dysfunction in Alzheimer's disease. , 2022, , 91-109.		0
645	Therapeutic approaches of nutraceuticals in the prevention of Alzheimer's disease. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	9
646	A CHCHD6-APP axis connects amyloid and mitochondrial pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 0, , .	3.9	3
648	Mitochondrial proteotoxicity: implications and ubiquitin-dependent quality control mechanisms. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	3
650	Impact prediction of translocation of the mitochondrial outer membrane 70 as biomarker in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
651	Immunosenescence and Aging: Neuroinflammation Is a Prominent Feature of Alzheimer's Disease and Is a Likely Contributor to Neurodegenerative Disease Pathogenesis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1817.	1.1	7
652	Mitochondria Transfer in Brain Injury and Disease. <i>Cells</i> , 2022, 11, 3603.	1.8	11
653	Amyloid precursor protein and mitochondria. <i>Current Opinion in Neurobiology</i> , 2023, 78, 102651.	2.0	10
654	Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	11
655	The Role of Caspases in Alzheimer's Disease: Pathophysiology Implications and Pharmacologic Modulation. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-20.	1.2	3
658	The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the 682YENPTY687 motif. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 923-930.	1.9	3
659	The Journey of Mitochondrial Protein Import and the Roadmap to Follow. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2479.	1.8	5
660	Interactions between amyloid, amyloid precursor protein, and mitochondria. <i>Biochemical Society Transactions</i> , 2023, 51, 173-182.	1.6	11
661	Antioxidant Thymoquinone and Its Potential in the Treatment of Neurological Diseases. <i>Antioxidants</i> , 2023, 12, 433.	2.2	7
662	Mitochondrial mechanisms in Alzheimer's disease: Quest for therapeutics. <i>Drug Discovery Today</i> , 2023, 28, 103547.	3.2	6

#	ARTICLE	IF	CITATIONS
663	Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. <i>Biochemical Pharmacology</i> , 2023, 211, 115522.	2.0	15
664	Isolated Mitochondrial Preparations and In organello Assays: A Powerful and Relevant Ex vivo Tool for Assessment of Brain (Patho)physiology. <i>Current Neuropharmacology</i> , 2023, 21, 1433-1449.	1.4	0
665	Mitochondrial cholesterol: Metabolism and impact on redox biology and disease. <i>Redox Biology</i> , 2023, 61, 102643.	3.9	14
666	Insights into the promising prospect of medicinal chemistry studies against neurodegenerative disorders. <i>Chemico-Biological Interactions</i> , 2023, 373, 110375.	1.7	1
667	The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 751-768.	1.2	19
668	Mitochondrial dysfunction rapidly modulates the abundance and thermal stability of cellular proteins. <i>Life Science Alliance</i> , 2023, 6, e202201805.	1.3	6
669	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7258.	1.8	7
670	Insights from <i>Drosophila</i> on A $\beta$ - and tau-induced mitochondrial dysfunction: mechanisms and tools. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
678	Amyloid $\beta$ -based therapy for Alzheimer's disease: challenges, successes and future. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	49
686	Ayurveda: Ayurvedic herbs against neurological disorders: are they golden nuggets?. , 2023, , 1-40.		0
690	Stem Cell-Based Therapy for Parkinson's Disease. , 2023, , 1-33.		0